Winrevair is a medicine used to improve the ability to exercise in adults with pulmonary arterial hypertension (PAH). Patients with PAH have an abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue. Winrevair is used in combination with other PAH medicines in patients with moderate or marked limitations of physical activity (corresponding to WHO functional class II or III respectively). PAH is rare, and Winrevair was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 December 2020. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2369). Winrevair contains the active substance sotatercept.
Therapeutic Indication
### Therapeutic indication Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity (see section 5.1).
Therapeutic Area (MeSH)
ATC Code
C02KX06
ATC Item
xc 02 kx 06
Pharmacotherapeutic Group
Antihypertensives
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| sotatercept | N/A | Sotatercept |
EMA Name
Winrevair
Medicine Name
Winrevair
Aliases
N/ANo risk management plan link.
